Incyte (INCY) Tops Q3 EPS by 33c; Jakafi Sales Up 63%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Goldman Sachs Upgrades Incyte (INCY) to Neutral
October 31, 2014 7:20 AM EDTGoldman Sachs upgraded Incyte (NASDAQ: INCY) from Sell to Neutral with a price target of $62.00 (from $32.00).
Analyst Navdeep Singh said, "Our Sell thesis was based on our more cautious view on Jakafis launch for myelofibrosis (MF) given safety and competition,... More
